Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
2 evidence topics · 2 sources
Deramiocel (CAP-1002)
Duchenne muscular dystrophy
- Manufacturer
- Capricor Therapeutics
- Regulatory submission
- Class 2 BLA resubmission submitted February 2026
- Launch
- Not announced
- Last updated